TYME announces outcome of interim futility review for HopES Sarcoma Phase II study
Principal Investigator of the HopES Sarcoma Study Recommended Continuation of the Trial BEDMINSTER, N.J.–(BUSINESS WIRE)–$TYME—Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today a positive outcome of an interim futility review for the HopES Sarcoma